World-first clinical trial for treating spinal cord injury
A Phase I human clinical trial is set to commence to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.
A Phase I human clinical trial is set to commence to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.
Griffith University’s BioSpine team, led by Dr Claudio Pizzolato, has won a coveted place in a health tech accelerator program...
A $3.8m funding boost for a crucial Griffith University research program focusing on digitally-enabled rehabilitation technology for spinal cord injury.
Griffith University’s world-first study into cell transplantation to repair injuries to the nervous system has received a major boost thanks to a $5.4 million funding extension from the MAIC.
A new partnership between Griffith and MAIC will examine the experiences of injured Aboriginal and Torres Strait Islanders and the Compulsory Third Party scheme.
Griffith medicine graduate and Biospine Project co-lead Dr Dinesh Palipana OAM has added Senior Lecturer in the School of Medicine to his growing list of Griffith affiliations.
World-leading Griffith research into the development of a cell-based therapy for treating spinal cord injuries has received a $5.7m boost from the state government.
Griffith has secured a $2m grant from the Motor Accident Insurance Commission for the BioSpine program.
Shannon Parry aims to showcase 'entertaining' sport at GC2018.